RhumbLine Advisers’s Alterity Therapeutics ATHE Stock Holding History
Bought
Maintained
Sold
Other funds holding ATHE
PFGI
RhumbLine Advisers's ATHE Position: Q3 2026 in Review
RhumbLine Advisers held its Alterity Therapeutics (ATHE) position steady in Q3 2026 at 2,009 shares worth $7.27K. The position accounts for ﹤0.01% of the portfolio, ranked #3863.
RhumbLine Advisers first reported a position in ATHE in Q1 2025 and has held it in 7 quarters since. The position peaked at $10.8K in Q2 2026. 22 funds tracked by Wall St. Rank hold ATHE as of Q3 2026.
- RhumbLine Advisers held 2,009 shares of Alterity Therapeutics worth $7.27K as of Q3 2026.
- RhumbLine Advisers left its Alterity Therapeutics share count unchanged in Q3 2026.
- Alterity Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q3 2026, its #3863 holding.
- RhumbLine Advisers first reported a position in Alterity Therapeutics in Q1 2025 and has held it in 7 quarters since.
- RhumbLine Advisers's Alterity Therapeutics position peaked at $10.8K in Q2 2026.
- 22 funds tracked by Wall St. Rank held Alterity Therapeutics as of Q3 2026.
Based on RhumbLine Advisers's 13F filing for Q3 2026, filed 10 Nov 2026.